Salix Presents Rifaximin Phase 3 Study Results for Irritable Bowel Syndrome with Diarrhea at Digestive Disease Week

Salix Presents Rifaximin Phase 3 Study Results for Irritable Bowel Syndrome with Diarrhea at Digestive Disease Week

WASHINGTON, June 3, 2018 /PRNewswire/ — Salix Pharmaceuticals, Ltd. (“Salix”), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, will present Phase 3 rifaximin study data at Digestive Disease Week (DDW) in Washington, D.C.,